These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-001782-18 Saftey and efficacy of two different doses of Neramexane mesylate as preemptive analgesic and add-on therapy to opioids in the management of postoperative pain. A randomised, double-blind, placebo-con... 2006-06-30 due-trials
Reported results Terminated 2004-002520-18 Safety and efficacy of Neramexane mesylate as add-on therapy to opioids in cancer patients for the management of chronic pain attributable to skeletal metastases: A randomised, double-blind, placebo-c... 2006-07-11 due-trials
Reported results 2005-001592-36 A Randomised, Double-Blind, Placebo-Controlled, Clinical Dose-Ranging Trial to Evaluate Efficacy and Safety of a NMDA antagonist for Oral Administration in Patients with Subjective Tinnitus 2007-03-08 due-trials
Completed, but no date, and reported results 2005-003951-11 Prospective, double-blind, placebo-controlled, randomized, multi-center trial with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke spast... bad-data
Reported results 2005-004416-78 A prospective, randomized, double-blind, placebo-controlled, multicenter trial with an open-label extension period to investigate the efficacy and safety of NT 201, free of complexing proteins, in the... 2007-11-29 due-trials
Reported results 2006-000073-29 Prospective, randomised, double-blind, placebo-controlled multicentre pilot trial to investigate the impact of an early use of NT 201 in patients with an acute cerebrovascular event on the development... 2008-07-02 due-trials
Reported results 2006-003036-30 Ensaio clínico prospectivo, randomizado, de observador cego, com grupos paralelos e multicêntrico, para avaliar a eficácia e a segurança de duas diluições diferentes de NT 201 em pacientes com espasti... 2008-07-28 due-trials
Reported results 2006-003410-18 Prospective, single-arm, multicenter trial to investigate the efficacy and safety of NT 201 (botulinum neurotoxin type A free of complexing proteins) and the duration of treatment effect after one inj... 2010-05-18 due-trials
Reported results 2006-003616-21 Prospective, single-arm, multi-center, open-label study to investigate the efficacy and tolerability of the once daily [OD] memantine treatment 2008-12-03 due-trials
Reported results 2006-005342-36 A prospective, open-label, multicenter, repeat-dose trial to investigate the safety and efficacy of NT 201, free of complexing proteins, in the treatment of glabellar frown lines 2009-12-28 due-trials
Reported results 2006-005396-17 A prospective, randomized, double-blind, international multicenter trial to investigate the efficacy and safety of NT 201 in comparison to placebo and to compare two different application schemes of... 2008-05-12 due-trials
Reported results Terminated 2007-000697-23 Prospective, single-arm, single-center, open-label trial to investigate the tolerability of NT 201 and quality of life of patients in the treatment of blepharospasm with shortened injection intervals 2008-02-28 due-trials
Reported results 2007-002595-34 Efficacy and safety of neramexane mesylate in congenital idiopathic nystagmus and acquired nystagmus: a randomized, double-blind, placebo-controlled, single center, proof of concept study using a two-... 2009-11-06 due-trials
Reported results 2007-004489-41 Prospective, single-arm, multi-center, open-label study to investigate the potential to reduce concomitant antipsychotics use in subjects with moderate dementia of Alzheimer’s type [DAT] treated with ... 2009-06-23 due-trials
Reported results Terminated 2007-007663-25 A Long-Term Open Label Extension Study to assess the Safety, Tolerability, and Efficacy of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus. 2010-06-10 due-trials
Reported results 2007-007835-16 A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus 2010-02-24 due-trials
Completed, but no date, and reported results 2008-000549-73 A prospective, open-label, international, multicenter trial to investigate the efficacy and safety of NT 201, free of complexing proteins, in the treatment of glabellar frown lines bad-data
Reported results 2008-000639-16 A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus 2010-06-22 due-trials
Reported results 2008-001432-13 An Open-Label, Long-Term Treatment Study to assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients with Subjective Tinnitus 2012-11-15 due-trials
Reported results 2008-002713-40 A prospective, multicenter, randomized, rater- and subject-blind, parallel group trial to investigate the non-inferiority of NT 201, free of complexing proteins, in comparison with Clostridium botulin... 2009-05-30 due-trials
Reported results 2008-005144-16 Open-label, single-arm, multi-center validation study of the ROSA-Scale (Relevant Outcome Scale for Alzheimer Patients) in patients with dementia of Alzheimer’s type (DAT) treated with memantine over ... 2009-11-11 due-trials
Reported results 2009-011246-25 MRZ 92579/TI/3003: A Randomized, Double-Blind, Placebo-Controlled, Clinical Evaluation of the Efficacy, Safety and Tolerability of Neramexane in Patients with Subjective Tinnitus 2011-06-03 due-trials
Reported results 2010-020737-50 Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of 10mg memantine in the treatment of memory, concentration or attention problems (s... 2011-09-12 due-trials
Reported results 2010-020886-26 Prospective, open-label, non-randomized, single-arm, multi-center dose titration study to investigate the safety and efficacy of NT 201 in subjects deemed to require total body doses of 800 U of NT 2... 2014-12-11 due-trials
Reported results 2010-023043-15 Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke spast... 2014-02-13 due-trials
Reported results 2010-024579-23 Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke spast... 2015-05-06 due-trials
Reported results 2011-001779-38 Prospective, randomized, double-blind, placebo-controlled, parallel-group, 3-stage dose-finding study to identify a safe and effective dose of NT 201 for unilateral injection into the soft palate for ... 2012-11-13 due-trials
Exempt, with results 2011-004998-83 A Double-Blind, Randomized, Dose Selection Vehicle–Controlled Multicenter Clinical Study for Evaluation of the Safety, Tolerability, Efficacy, and Pharmacokinetics of topical Neramexane in Subjects wi... 2013-07-09 not-yet-due
Reported results 2011-005887-20 A prospective, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the combined treatment of upper f... 2013-10-05 due-trials
Reported results 2012-004821-26 Prospective, double-blind, placebo-controlled, randomized, parallel-group, multi-center study with an open-label extension period to investigate the efficacy and safety of two different doses of NT 20... 2016-11-10 due-trials
Trial is partly outside EEC, and reported results 2012-005054-30 Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of lower limb spasticity in children and ... 2017-05-24 bad-data
Trial is partly outside EEC, and reported results 2012-005055-17 Open-label, non-controlled, multicenter long-term study to investigate the safety and efficacy of Xeomin® (incobotulinumtoxin A, NT 201) for the treatment of spasticity of the lower limb(s) or of comb... 2017-01-16 bad-data
Trial is partly outside EEC, and reported results 2012-005496-14 Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of upper limb spasticity alone or combine... 2018-08-28 bad-data
Reported results 2012-005539-10 Prospective, randomized, double-blind, placebo-controlled, parallel-group multicenter study, with an extension period of dose-blinded active treatment, to investigate the efficacy and safety of two do... 2016-11-09 due-trials
Trial is partly outside EEC, and reported results 2013-004532-30 Prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of ch... 2019-05-07 bad-data
Reported results 2014-003770-16 A prospective, open-label, multicenter, repeat-dose trial to investigate the safety and efficacy of NT 201 (incobotulinumtoxinA) in the combined treatment of upper facial lines (horizontal forehead li... 2016-12-08 due-trials
Trial is outside EEC, and reported results 2016-005049-21 Multi-center Open Comparative Randomized Trial of Clinical and Neurophysiological Efficacy and Safety of Xeomin (Botulinum Toxin Type A) vs. Botox (Complex of Botulinum Toxin Type A and Hemagglutinin)... bad-data
Ongoing 2018-001639-35 Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity caused by stroke or traumatic br... not-yet-due
Reported results 2019-004113-13 A prospective, randomized, double-blind, placebo-controlled, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the simultaneous treatment of upp... 2022-07-08 due-trials
No trial status on register 2021-001634-18 A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower... bad-data